loading...| Preferred Name |
lopinavir |
|
| Synonyms |
ABT-378/r |
|
| Definitions |
A protease inhibitor used against human immunodeficiency virus (HIV). Lopinavir competitively inhibits the HIV-1 protease, an enzyme that mediates the cleavage of Gag, Gag-Pol and Nef precursor polypeptides into their mature proteins, including protease, reverse transcriptase, and integrase. Inhibition of HIV-1 protease prevents cleavage of the viral polyprotein precursor and results in the release of immature, noninfectious virions. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2095" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2095" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000540623 |
|
| altLabel |
ABT-378/r |
|
| CAS Registry |
192725-17-0 |
|
| cui |
C1527135 C0674432 |
|
| DATE FIRST PUBLISHED |
2007-04-02 |
|
| definition |
A protease inhibitor used against human immunodeficiency virus (HIV). Lopinavir competitively inhibits the HIV-1 protease, an enzyme that mediates the cleavage of Gag, Gag-Pol and Nef precursor polypeptides into their mature proteins, including protease, reverse transcriptase, and integrase. Inhibition of HIV-1 protease prevents cleavage of the viral polyprotein precursor and results in the release of immature, noninfectious virions. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2095" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2095" NCI Thesaurus) |
|
| NCI ID |
C2095 |
|
| notation |
CDR0000540623 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
lopinavir |
|
| tui |
T109 T121 |